Related resources
Full-text held externally
- DOI: 10.1586/eci.11.98
- PMID: 22390487
- UKPMCID: 22390487
Search for item elsewhere
University researcher(s)
Academic department(s)
Abatacept in the long-term treatment of rheumatoid arthritis.
Expert review of clinical immunology. 2012;8(3):231-4.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
- DOI: 10.1586/eci.11.98
- PMID: 22390487
- UKPMCID: 22390487
Abstract
The last decade has been an era of exciting and innovative therapeutic targets in the treatment of moderate-to-severe rheumatoid arthritis. One such treatment that acts by disrupting T-cell activation is abatacept, which is currently used in patients who have had an inadequate clinical response to traditional disease-modifying drugs or anti-TNF therapies. As newer therapies emerge, issues that need addressing include: long-term drug tolerance, adverse events, sustained clinical response, prevention of progression in structural damage and retention rates. In this article we discuss a recently published paper by Kremer et al. that reported 3-year data on safety, efficacy and radiographic progression in patients enrolled in a clinical trial of abatacept, as well as the advantages and limitations of long-term extension studies.